市场调查报告书
商品编码
1296882
2023-2030年全球过敏性免疫疗法市场Global Allergy Immunotherapy Market 2023-2030 |
胃肠道疾病的发病率越来越高,生命科学研究领域的投资和资金不断增加,这些因素在预测期内促进了过敏免疫疗法市场的增长。过敏免疫疗法也被称为低敏化。它是一种医疗手段,可以解决各种类型的过敏问题。在全球范围内,各种类型的过敏症都有明显的增长。药物治疗不足以解决和控制这些过敏性疾病的发生。因此,这是过敏免疫疗法市场发展的一个主要驱动因素。使用这些治疗方法能够建立起对过敏物质的耐受性,并能够改变疾病的进程。
全球过敏症免疫疗法市场根据治疗方法、类型和分销渠道进行细分。根据类型,市场被划分为过敏性鼻炎、过敏性哮喘、食物过敏、药物过敏和其他。由于全球范围内哮喘的发病率越来越高,预计哮喘部分将占据重要的市场份额。根据治疗方法,市场被分为皮下免疫疗法和舌下免疫疗法。在预测期内,皮下免疫疗法部分预计将保持相当大的增长率,因为它能有效地治疗一些过敏症,如哮喘。此外,它是必须改变一个人的免疫系统以治愈其他过敏症发展的治疗方案。根据分销渠道,市场被细分为医院药店、零售药店和网上药店。
过敏性鼻炎将是最大的部分
Global allergy immunotherapy market is anticipated to grow at a CAGR of 8.2% during the forecast period. Factor such as increasing awareness of allergies in patients is anticipated to propel the growth of the allergy immunotherapy industry. According to the World Allergy Organization, an increase in the pervasiveness of allergies has been witnessed and around 30% of the world population has allergic rhinitis. As per the Centers for Disease Control and Prevention (CDC), more than 8% of adults in the US suffer from sinusitis and hay fever. With the awareness created by these organizations; governments of different countries have sanctioned budgets for the R&D of allergy immunotherapy as an effective cure. Thus, this factor has a positive impact on the growth of the allergy immunotherapy market during the forecast period.
The factors such as the growing prevalence of gastrointestinal diseases, rising investments, and funding in the field of life science research boost the growth of the allergy immunotherapy market during the forecast period. Allergy immunotherapy is also known as hypo-sensitization. It is a type of medical treatment that allows for tackling various types of allergies. There has been significant growth in the various types of allergies across the globe. Pharmacotherapy is not enough to tackle and control the occurrence of these allergic disorders. Therefore, it is a major driving factor for the development of the allergy immunotherapy market. The use of these treatments enables building up the tolerance level against the allergic substances and enables altering the course of the disorders.
The global allergy immunotherapy market is segmented based on treatment, type, and distribution channel. Based on type, the market is segmented into allergic rhinitis, allergic asthma, food allergy, drug allergy, and others. The asthma segment is expected to hold a significant market share due to the growing prevalence of asthma across the globe. Based on treatment, the market is bifurcated into subcutaneous immunotherapy and sublingual immunotherapy. The subcutaneous immunotherapy segment is expected to hold a considerable growth rate during the forecast period due to its effectiveness in treating several allergies such as asthma. Moreover, it is treatment options that have to alter one's immune system to cure the development of other allergies. Based on the distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Allergic Rhinitis will be the largest segment
Based on type, the market is segmented into allergic rhinitis, allergic asthma, food allergy, drug allergy, and others. The allergic rhinitis segment is expected to hold the largest market share in the allergy immunotherapy market. As per the Center for CDC around 8% of the total population is suffering from allergic rhinitis in the US. Therefore, the rising prevalence among adults and children is expected to propel the growth of the segment.
Regional Outlooks
The global Allergy Immunotherapy market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among these, the Europe market is anticipated to cater to a prominent growth over the forecast period. However, the Asia-Pacific region is projected to experience considerable growth in the Allergy Immunotherapy market.
Among these regions, the Asia-Pacific region is anticipated to account for a significant share of the Allergy Immunotherapy market during the forecast period. The growth of the allergy immunotherapy market in the region is primarily driven by factors such as the growing number of patients suffering from various types of allergies, and the growing prevalence of chronic diseases such as hypertension, asthma, allergies, and diabetes that fuel the growth of the allergy immunotherapy market. Along with it, the growing prevalence of allergic asthma, eczema, and food allergy improved healthcare facilities, growing funds from R&D, and the development of new products and therapy is also contributed to the market share in the region.
Market Players Outlook
The key players of the allergy immunotherapy market include Biomay AG, Aimmune Therapeutics, Inc., HAL Allergy Group, Allergopharma, Merck KGaA, Stallergenes Greer, Jubilant Life Sciences, Ltd., ALK-Abello A/S, Leti Pharma, and DBV Technologies. These market players are continuously adopting various strategies to expand their market share. For instance, in November 2018, Aimmune Therapeutics, Inc announced the closing of the $98 million equity investment by Nestle Health Science. The funding was provided to develop treatments for potentially life-threatening food allergies. Further, in October 2017, DBV Technologies entered into an R&D agreement for the treatment of birch allergies with standergness SA.